MedTrace Logo

A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients

NCT04005066 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3005

Last updated 2022-12-19

No results posted yet for this study

Summary

A phase IV study to characterize safety of Elunate® (Fruquintinib) in Chinese patients

Conditions

  • Patient Safety

Interventions

DRUG

Elunate®

The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Mandy Xue · Hutchmed

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-20
Primary Completion
2022-09-27
Completion
2022-09-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04005066 on ClinicalTrials.gov